Provided by Tiger Fintech (Singapore) Pte. Ltd.

Annexon, Inc.

2.89
+0.08002.85%
Post-market: 2.910.0200+0.69%16:59 EDT
Volume:1.88M
Turnover:5.62M
Market Cap:317.07M
PE:-2.48
High:3.11
Open:2.85
Low:2.74
Close:2.81
Loading ...

Annexon Up Over 18%, on Pace For Highest Close Since February -- Data Talk

Dow Jones
·
Yesterday

Annexon Inc. Unveils Visionary Plan to Revolutionize Treatment for Complement-Mediated Diseases

Reuters
·
25 Jun

BRIEF-Annexon says enrollment of Phase 3 Archer II Trial expected to be completed in Q3 2025

Reuters
·
19 Jun

Annexon Inc - Enrollment of Phase 3 Archer Ii Trial Expected to Be Completed in Q3 2025, With Topline Data Expected in Second Half of 2026

THOMSON REUTERS
·
19 Jun

Annexon Inc. Strengthens Ophthalmology Team with Appointment of Dr. Lloyd Clark as Senior VP to Lead Pivotal ANX007 Program in AMD Treatment

Reuters
·
19 Jun

Annexon Biosciences Holds Annual Stockholders Meeting

TIPRANKS
·
10 Jun

Annexon Inc. Concluded Annual Stockholders Meeting

Reuters
·
10 Jun

Annexon Inc. Announces CEO Douglas Love to Present at Jefferies Global Healthcare Conference

Reuters
·
30 May

Annexon presents tanruprubart data at PNS annual meeting

TIPRANKS
·
20 May

BRIEF-Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
17 May

Annexon Inc. Announces Inducement Grants for New Employees Under 2022 Employment Inducement Award Plan

Reuters
·
17 May

Annexon price target lowered to $14 from $20 at H.C. Wainwright

TIPRANKS
·
13 May

Annexon Is Maintained at Buy by Needham

Dow Jones
·
13 May

Annexon Biosciences Reports Increased Q1 2025 Losses

TIPRANKS
·
13 May

TD Cowen Sticks to Its Buy Rating for Annexon Biosciences (ANNX)

TIPRANKS
·
13 May

Annexon Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
12 May

Annexon Q1 EPS $(0.37) Misses $(0.29) Estimate

Benzinga
·
12 May

Annexon Inc expected to post a loss of 30 cents a share - Earnings Preview

Reuters
·
10 May

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
17 Apr

Annexon Biosciences’ ANX005: Promising Phase III Results and Strategic Initiatives Drive Buy Rating

TIPRANKS
·
10 Apr